Загрузка...
The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention
BACKGROUND: Using novel small-molecular inhibitors, we explored the feasibility of the class I PI3K/Akt/mTORC1 signaling pathway as a therapeutic target in canine oncology either by using pathway inhibitors alone, in combination or combined with conventional chemotherapeutic drugs in vitro. RESULTS:...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3515332/ https://ncbi.nlm.nih.gov/pubmed/22647622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1746-6148-8-73 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|